Actively Recruiting
Social Isolation and Aging in Schizophrenia
Led by Icahn School of Medicine at Mount Sinai · Updated on 2026-02-19
650
Participants Needed
4
Research Sites
181 weeks
Total Duration
On this page
Sponsors
I
Icahn School of Medicine at Mount Sinai
Lead Sponsor
N
National Institute of Mental Health (NIMH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Individuals diagnosed with schizophrenia and related psychotic disorders (SZ) exhibit a markedly elevated risk of premature mortality, with a 10-20-year shorter lifespan relative to the general population. Increased mortality rates in SZ are largely attributable to the early manifestation of medical conditions that normally occur later in life, a process known as 'accelerated aging'. While unhealthy lifestyle behaviors, such as smoking and unhealthy diet, account, in part, for accelerated aging in SZ, the excess of physical comorbidities cannot be solely attributed to these factors. Remarkably, the direct adverse health effects of key clinical characteristics of SZ have rarely been considered. In the general population, the absence of social contact is known to pose enormous challenges for physical health, especially at older ages. Given that social isolation is a persistent and disabling feature of SZ, it is possible that this behavior may contribute to the premature manifestation of health conditions in SZ. Building on rich pilot data pointing to significant associations between social isolation and long-term perceived health in SZ, the overarching goal is to test whether and how social isolation contributes to the health challenges of individuals with SZ as they age. With participants from Europe (EU-GEI) and the US (Olin Neuropsychiatry Research Center), the researchers will create a longitudinal database of 650 participants, including 500 individuals with SZ, and 150 of their unaffected siblings. The researchers will apply an accelerated longitudinal design by reassessing and by examining medical records of research participants who were first evaluated between the ages of 20-55 and are now 40-70 years of age, a period when many medical conditions and health problems tend to manifest. The researchers will determine the age-related association between social isolation and adverse health outcomes in SZ, test for familiality, directionality, and factors moderating this association, and determine the extent to which the COVID-19 pandemic and the resulting imposed lockdowns impacted health in SZ. The researchers will consider generalizability across countries, sexes, and race/ethnicities. The rationale for the proposed research is that in order to facilitate much-needed targeted therapies to prevent early mortality in SZ, the researchers need to better understand factors that contribute to the excess of medical comorbidities in SZ. The central hypothesis is that social isolation, a common and persistent characteristic of SZ, contributes to the excess of physical comorbidities in SZ. To meet the overall goal, the following aims are: (1) Determine the association between social isolation and adverse health outcomes in SZ; (2) Test for the directionality, and moderating factors, of the association between social isolation and health outcomes in SZ, and; (3) Examine whether the COVID-19 pandemic modified associations between social isolation and health outcome in SZ. This study will be the first to comprehensively examine the health impact of social isolation in SZ. The project may show that in SZ socialization in midlife can reduce the risk for poor health outcomes and ultimately facilitate much-needed preventive targeted therapies to reduce early-age mortality in SZ
CONDITIONS
Official Title
Social Isolation and Aging in Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of schizophrenia or related disorder based on clinical interview (DSM-IV or V codes 295.x, 297.1, 298.8, or 298.9)
- Age between 40 and 70 years at study recruitment
- Previously enrolled in a research study between ages 20 and 55 at least 5 years ago
- Ability to understand the spoken language of the participating country
- No history of serious head injury with prolonged loss of consciousness or cognitive rehabilitation
- No history of IQ below 70 or developmental disability
- Clinically stable: no inpatient hospitalizations for 3 months and no medication changes in 4 weeks prior to enrollment
You will not qualify if you...
- Diagnosis of psychotic disorder solely induced by substance use
- History of serious head injury (loss of consciousness longer than 1 hour, neuropsychological sequelae, or cognitive rehabilitation)
- History of IQ below 70 or developmental disability
- Not clinically stable: inpatient hospitalizations within 3 months or medication changes within 4 weeks
- Siblings with any DSM IV/V Axis I or II diagnosis affecting social functioning (e.g., severe mood disorder, schizoaffective personality disorder, autism spectrum disorder)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Olin Neuropsychiatry Research Center, Hartfort
Hartford, Connecticut, United States, 06106
Actively Recruiting
2
AUMC, University Hospital
Amsterdam, North Holland, Netherlands, 1105AZ
Actively Recruiting
3
Hospital General Universitario Gregorio Marañon
Madrid, Spain, 28030
Actively Recruiting
4
King's College London
London, United Kingdom, Se58AF
Actively Recruiting
Research Team
E
Eva Velthorst, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here